What Is Cannabinol (CBN)?
Cannabinol (CBN) is a non-intoxicating, lightly active phytocannabinoid found in Cannabis sativa. Historically, it was the first cannabinoid ever isolated from cannabis — Robert S. Cahn first characterized the molecule in the 1930s, more than a decade before THC and CBD were structurally identified (Maioli et al., 2022).
CBN is unusual among the major cannabinoids because the plant does not produce it directly. Rather, CBN forms over time as Δ⁹-tetrahydrocannabinolic acid (THCA) and Δ⁹-tetrahydrocannabinol (THC) oxidize when exposed to oxygen, heat, and ultraviolet light. For that reason, the highest CBN concentrations are typically found in aged or improperly stored cannabis flower, not in fresh material (Lindholst, 2010; Maioli et al., 2022).
This article reviews what the peer-reviewed literature actually shows about CBN: its receptor pharmacology, the most-cited preclinical findings, and the small but growing body of human data — including the popular but often-overstated claim that CBN is a sleep aid.
How CBN Forms in Cannabis
CBN is best understood as a degradation product rather than a biosynthesized cannabinoid:
1. The plant produces THCA enzymatically from CBGA via THCA synthase (Sirikantaramas et al., 2004). 2. With time and exposure to air, THCA can lose two hydrogen atoms through oxidation, forming cannabinolic acid (CBNA). 3. With further heat or UV exposure, CBNA decarboxylates to CBN, and any remaining THC oxidizes to CBN as well (Lindholst, 2010).
This means CBN concentration is essentially a chemical clock. Fresh, well-cured cannabis flower contains very little CBN — typically under 1% by weight — while aged flower stored at room temperature can accumulate measurable CBN over months to years. Heat alone can also drive the conversion, which is why some commercial CBN is produced by deliberately oxidizing THC distillate.
Because CBN is the end product of THC degradation, the long-standing forensic ratio of CBN to THC in seized cannabis has been used as a rough indicator of sample age (UNODC Bulletin, 1997).
CBN’s Pharmacology: Receptor and Channel Activity
The pharmacology of CBN is more modest than its reputation suggests.
Cannabinoid receptors (CB1 and CB2). CBN binds CB1 and CB2 with notably lower affinity than THC. Reported binding constants (Ki) are approximately 211 nM at CB1 and 126 nM at CB2 — about an order of magnitude weaker than THC at CB1 (Rhee et al., 1997). Functional studies describe CBN as a weak partial agonist at both receptors, with somewhat greater preference for CB2.
Other targets. CBN has been reported to interact with TRPA1 and TRPV2 channels in cell-based screens (De Petrocellis et al., 2011), and to weakly affect 5-HT (serotonin) receptors and other off-target sites. A 2025 medicinal-chemistry paper characterized several CBN cytochrome-P450–generated metabolites and found that some have distinct receptor and sensory-neuron interactions different from CBN itself (Lewis-Bakker et al., 2025).
Key takeaway. CBN is a low-affinity, weakly active cannabinoid. Many of the effects attributed to CBN in the consumer market are either (a) extrapolated from older animal studies that used very high doses, (b) attributable to residual THC in CBN preparations, or (c) attributable to terpenes and other cannabinoids in full-spectrum products. The most widely circulated claim — that CBN is strongly sedating — is not well supported by direct, isolated CBN human research, as discussed below.
Areas of Preclinical Research
Most of what is known about CBN in disease models comes from animal and cell-culture work.
Neuroprotection (ALS)
In an often-cited study, Weydt et al. (2005) administered CBN (5 mg/kg/day, subcutaneous, over 12 weeks) to SOD1 G93A transgenic mice — a standard model of amyotrophic lateral sclerosis (ALS). CBN delayed the onset of motor symptoms but did not extend overall survival. The authors attributed the effect to CBN’s residual CB1 activity and possible antioxidant action. The findings have not been replicated in larger animal studies or extended to human ALS trials.
Antibacterial activity
Appendino et al. (2008), in their landmark MRSA-screening study of major cannabinoids, reported that CBN inhibited several methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates with minimum inhibitory concentrations (MICs) in the 1–2 µg/mL range — broadly comparable to vancomycin in vitro. CBN has not been clinically tested as an antimicrobial.
Appetite
Farrimond et al. (2012) reported that CBN increased food intake in pre-satiated rats, reducing the latency to feed and increasing meal size — opposite to CBD, which suppressed feeding in the same paradigm. The effect was attributed to weak CB1 receptor activity. This is the most-cited preclinical evidence for an “appetite stimulant” claim, though it has not been replicated in controlled human studies.
Other preclinical signals
Smaller bodies of work describe CBN in models of glaucoma (intraocular pressure), pain (tetanic-pain and inflammatory-pain protocols), and bone-cell differentiation. Most are dated, single-laboratory findings. The 2022 review by Maioli and colleagues catalogues the breadth of this literature and consistently emphasizes the same caveat: most CBN data are old, used non-validated methods, and have not been independently replicated.
What the Limited Human Data Show
CBN’s reputation as the “sleep cannabinoid” deserves direct scrutiny against the actual published evidence.
The historical narrative is thin
A 2021 narrative review by Corroon screened 99 human studies and identified only eight that met inclusion criteria for any CBN-specific analysis. The author concluded that the published evidence does not adequately support sleep-related claims, that most early studies used very small samples or co-administered CBN with THC (confounding the results), and that no published clinical trial at that point had assessed CBN’s effects using polysomnography or validated sleep questionnaires (Corroon, 2021).
A modern RCT (Bonn-Miller et al., 2023)
The most rigorous human study of CBN to date is a double-blind, randomized, placebo-controlled trial published by Bonn-Miller and colleagues in 2023. The trial enrolled 293 adults reporting “poor” or “very poor” sleep, and randomized them to one of five conditions for seven consecutive nights: placebo, 20 mg CBN alone, or 20 mg CBN combined with 10 mg, 20 mg, or 100 mg CBD.
Results, in the modified intent-to-treat analysis:
- 20 mg CBN produced a non-significant but potentially clinically meaningful improvement in overall sleep quality versus placebo.
- 20 mg CBN significantly reduced the number of nighttime awakenings and overall sleep disturbance.
- There was no significant effect on sleep onset latency, wake after sleep onset (WASO), or next-day fatigue.
- Adding CBD at any of three doses did not improve outcomes beyond CBN alone.
This is, at the time of writing, the strongest human evidence for any sleep-related claim about CBN, and it is meaningfully more modest than typical marketing language (“CBN puts you to sleep”). The findings are consistent with a small, mostly sleep-maintenance effect at 20 mg, not a strong sedative.
Ongoing trials
The Australian “CUPID” trial (Suraev et al., 2023) is testing 30 mg and 300 mg CBN doses against placebo in adults with chronic insomnia, using polysomnography as the primary outcome. Results from CUPID and similar studies should substantially clarify CBN’s true effect size in the next several years.
Safety, Drug Interactions, and What’s Not Known
CBN has not been associated with intoxication in published clinical research at doses of 5–300 mg. Acute adverse-event profiles in the Bonn-Miller et al. (2023) trial were mild and similar to placebo. However, several practical knowledge gaps remain:
- Cytochrome P450 interactions. CBN inhibits multiple CYP450 enzymes in vitro (Nasrin et al., 2021), which could affect the metabolism of common prescription drugs. This has not been characterized clinically.
- Drug testing. CBN is not the analyte detected by standard workplace drug screens, but products that include CBN derived from full-spectrum extracts may contain trace THC, which can contribute to a positive screen.
- Pregnancy and lactation. No human safety data exist; CBN should be avoided in these populations.
- Product variability. Independent testing has documented discrepancies between labeled and measured cannabinoid content in commercial products (Bonn-Miller et al., 2017). For CBN specifically, isolation routes (natural aging vs. synthetic THC oxidation) can leave trace impurities, so verified third-party Certificates of Analysis are advisable.
The U.S. Food and Drug Administration has not approved CBN for the treatment, prevention, cure, or diagnosis of any medical condition. Anyone considering CBN, particularly for sleep concerns or alongside prescription medications, should speak with a qualified medical professional first. Persistent insomnia is a clinical condition that warrants evaluation, not self-treatment with under-studied supplements.
Frequently Asked Questions
Is CBN psychoactive?
In the published peer-reviewed literature, isolated CBN at typical product doses (5–30 mg) has not produced THC-like intoxication. At very high doses CBN may produce mild psychoactive effects through its weak CB1 activity, but this has not been a feature of modern controlled trials (Bonn-Miller et al., 2023; Corroon, 2021).
Does CBN actually help sleep?
The best-controlled human evidence — Bonn-Miller et al. (2023) — found that 20 mg CBN reduced nighttime awakenings and overall sleep disturbance versus placebo, with a non-significant trend on overall sleep quality. It did not affect time to fall asleep or next-day fatigue. The effect is modest, not the strong sedative implied by some marketing.
Is CBN the same as old THC?
In a sense, yes. CBN forms when THC and THCA oxidize over time. Aged cannabis flower contains higher CBN; fresh, properly stored flower contains very little (Lindholst, 2010). Some commercial CBN is produced by deliberately oxidizing THC distillate.
Will CBN show up on a drug test?
Standard urine drug screens look for the THC metabolite THC-COOH, not CBN. However, commercial CBN products derived from hemp can contain residual THC, which can produce positive screens, especially with frequent use.
How is CBN different from CBD?
CBN and CBD are both non-intoxicating cannabinoids, but they are chemically distinct and engage different targets. CBD has substantially more clinical data, including FDA approval (as Epidiolex) for specific seizure disorders, and is generally not associated with sleep-maintenance effects in the way CBN tentatively is. They are not interchangeable.
References
Appendino, G., Gibbons, S., Giana, A., Pagani, A., Grassi, G., Stavri, M., Smith, E., & Rahman, M. M. (2008). Antibacterial cannabinoids from Cannabis sativa: A structure–activity study. Journal of Natural Products, 71(8), 1427–1430. https://doi.org/10.1021/np8002673
Bonn-Miller, M. O., Feldner, M. T., Bynion, T.-M., Eglit, G. M. L., Brunstetter, M., Kalaba, M., Hennesy, M., & Buchwald, D. (2023). A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality. Experimental and Clinical Psychopharmacology. Advance online publication. https://doi.org/10.1037/pha0000683
Bonn-Miller, M. O., Loflin, M. J. E., Thomas, B. F., Marcu, J. P., Hyke, T., & Vandrey, R. (2017). Labeling accuracy of cannabidiol extracts sold online. JAMA, 318(17), 1708–1709. https://doi.org/10.1001/jama.2017.11909
Corroon, J. (2021). Cannabinol and sleep: Separating fact from fiction. Cannabis and Cannabinoid Research, 6(5), 366–371. https://doi.org/10.1089/can.2021.0006
De Petrocellis, L., Ligresti, A., Moriello, A. S., Allarà, M., Bisogno, T., Petrosino, S., Stott, C. G., & Di Marzo, V. (2011). Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. British Journal of Pharmacology, 163(7), 1479–1494. https://doi.org/10.1111/j.1476-5381.2010.01166.x
Farrimond, J. A., Whalley, B. J., & Williams, C. M. (2012). Cannabinol and cannabidiol exert opposing effects on rat feeding patterns. Psychopharmacology, 223(1), 117–129. https://doi.org/10.1007/s00213-012-2697-x
Lewis-Bakker, M. M., Yang, Y., Vyawahare, R., & Kotra, L. P. (2025). Distinct interactions of cannabinol and its cytochrome P450-generated metabolites with receptors and sensory neurons. Journal of Medicinal Chemistry. Advance online publication. https://doi.org/10.1021/acs.jmedchem.5c00938
Lindholst, C. (2010). Long term stability of cannabis resin and cannabis extracts. Australian Journal of Forensic Sciences, 42(3), 181–190. https://doi.org/10.1080/00450610903258144
Maioli, C., Mattoteia, D., Amin, H. I. M., Minassi, A., & Caprioglio, D. (2022). Cannabinol: History, syntheses, and biological profile of the greatest “minor” cannabinoid. Plants, 11(21), 2896. https://doi.org/10.3390/plants11212896
Nasrin, S., Watson, C. J. W., Perez-Paramo, Y. X., & Lazarus, P. (2021). Cannabinoid metabolites as inhibitors of major hepatic CYP450 enzymes, with implications for cannabis–drug interactions. Drug Metabolism and Disposition, 49(12), 1070–1080. https://doi.org/10.1124/dmd.121.000442
Rhee, M. H., Vogel, Z., Barg, J., Bayewitch, M., Levy, R., Hanus, L., Breuer, A., & Mechoulam, R. (1997). Cannabinol derivatives: Binding to cannabinoid receptors and inhibition of adenylylcyclase. Journal of Medicinal Chemistry, 40(20), 3228–3233. https://doi.org/10.1021/jm970126f
Sirikantaramas, S., Morimoto, S., Shoyama, Y., Ishikawa, Y., Wada, Y., Shoyama, Y., & Taura, F. (2004). The gene controlling marijuana psychoactivity: Molecular cloning and heterologous expression of Δ¹-tetrahydrocannabinolic acid synthase from Cannabis sativa L. Journal of Biological Chemistry, 279(38), 39767–39774. https://doi.org/10.1074/jbc.M403693200
Suraev, A. S., Marshall, N. S., Vandrey, R., McCartney, D., Benson, M. J., McGregor, I. S., Grunstein, R. R., & Hoyos, C. M. (2023). Cannabinol (CBN; 30 and 300 mg) effects on sleep and next-day function in insomnia disorder (“CUPID” study): Protocol for a randomised, double-blind, placebo-controlled, cross-over, three-arm, proof-of-concept trial. BMJ Open, 13(8), e072305. https://doi.org/10.1136/bmjopen-2023-072305
Weydt, P., Hong, S., Witting, A., Möller, T., Stella, N., & Kliot, M. (2005). Cannabinol delays symptom onset in SOD1 (G93A) transgenic mice without affecting survival. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 6(3), 182–184. https://doi.org/10.1080/14660820510030149
